Edgar Filing: GLAXOSMITHKLINE PLC

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending February 2009

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No x
--

Notification of Transactions of Directors and

Persons Discharging Managerial Responsibility

I give below details of changes in the interests of:

Persons Discharging Managerial Responsibility in the Ordinary shares of GlaxoSmithKline plc in respect of the under mentioned persons arising from the sale of Ordinary shares at a price of £11.33 per Ordinary share on 23 February 2009 to meet their tax liabilities following the vesting of a Share Value Plan award:

	No. of Shares Awarded	No. of Shares Sold	No. of Shares Retained
Mr S M Bicknell	3,160	1,296	1,864
Mr E J Gray	3,350	1,374	1,976
Mr D Learmouth	3,160	1,296	1,864
Mr D S Redfern	3,350	1,374	1,976
Ms C Thomas	2,520	1,034	1,486

Persons Discharging Managerial Responsibility in the American Depositary Shares (ADSs) of GlaxoSmithKline plc in respect of the under mentioned person arising from the sale of ADSs at a price of $32.55 per ADS on 23 February 2009 to meet his tax liabilities following the vesting of a Share Value Plan award:

	No. of ADSs Awarded	No. of ADSs Sold	No. of ADSs Retained
Mr W C Louv	1,480	496	984

The Company and Persons Discharging Managerial Responsibility were advised of these transactions on 24 February 2009.

This notification relates to a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

V A Whyte

Deputy Company Secretary

24 February 2009

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: February 24 2009

By: VICTORIA WHYTE

------------------

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc